Krystal Biotech, Inc. Share Price
KRYSKrystal Biotech, Inc. Stock Performance
Open $375.80 | Prev. Close $377.43 | Circuit Range N/A |
Day Range $370.19 - $382.01 | Year Range $130.50 - $382.01 | Volume 12,326 |
Average Traded $375.38 |
Krystal Biotech, Inc. Share Price Chart
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Krystal Biotech, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
30-Jun-26 | $375.80 | $371.74 | +0.00% |
30-Jun-26 | $375.80 | $371.74 | -1.72% |
29-Jun-26 | $368.82 | $378.23 | +1.73% |
26-Jun-26 | $360.08 | $371.78 | +3.31% |
25-Jun-26 | $347.62 | $359.86 | +3.46% |
24-Jun-26 | $348.75 | $347.81 | +2.19% |
23-Jun-26 | $340.56 | $340.35 | -0.90% |